Christof M Kramm

Title: Christof M Kramm: Innovator in Antifolate Drug Sensitivity

Introduction

Christof M Kramm is a notable inventor based in Duesseldorf, Germany. He has made significant contributions to the field of cancer treatment through his innovative research and patent work. His focus on enhancing the effectiveness of antifolate drugs has the potential to improve therapeutic outcomes for patients with neoplastic diseases.

Latest Patents

Kramm holds a patent for a method involving the transfer of the folylpolyglutamyl synthetase (FPGS) gene. This invention aims to enhance the sensitivity of various tumor cells to polyglutamylatable antifolate drugs, such as methotrexate (MTX) and edatrexate (EDX). The patent is titled "Folypolyglutamyl synthetase gene transfer to enhance antifolate - Methods of killing neoplastic cells" and represents a significant advancement in cancer treatment methodologies. He has 1 patent to his name.

Career Highlights

Kramm is associated with The General Hospital Corporation, where he continues to work on innovative solutions in the medical field. His research has been pivotal in understanding how gene transfer can be utilized to improve drug efficacy against cancer cells.

Collaborations

Throughout his career, Kramm has collaborated with esteemed colleagues, including Manish Aghi and Xandra O Breakefield. These partnerships have fostered a collaborative environment that enhances research and development in cancer therapies.

Conclusion

Christof M Kramm's work in the field of antifolate drug sensitivity showcases his commitment to advancing cancer treatment. His innovative approaches and collaborations highlight the importance of research in improving patient outcomes.